.

Cara Therapeutics reported $-4206000 in Net Income for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Acadia Pharmaceuticals ACAD:US $ -34.01M 79.04M
Acelrx Pharmaceuticals ACRX:US $ 70.66M 79.34M
Aerie Pharmaceuticals AERI:US $ -19.37M 16.52M
Cara Therapeutics CARA:US $ -4206000 23.54M
Chugai Pharma 4519:JP Y 72378M 59397M
Depomed DEPO:US $ 7.83M 1.23M
Endo International Ordinary Shares ENDP:US $ -1885.43M 1813.45M
Halozyme Therapeutics HALO:US $ 22.68M 37.42M
Horizon Pharma HZNP:US $ 60.97M 143.29M
JAZZ PHA JAZZ:US $ 34.66M 33.02M
Johnson & Johnson JNJ:US $ 4814M 335M
Neurocrine Biosciences NBIX:US $ -16.9M 30.8M
Pacira Pharmaceuticals PCRX:US $ 19.88M 13.05M
Pain Therapeutics PTIE:US $ -19.33M 1.8M
Pfizer PFE:US $ 9905M 2042M
Redhill Biopharma RDHL:US $ -17.14M 7.24M
Revance Therapeutics RVNC:US $ -61.44M 2.91M
Supernus Pharmaceuticals SUPN:US $ 7.86M 17.75M
Teva Pharmaceutical Industries TEVA:US $ -233M 722M